Lyell Immunopharma (LYEL) Current Assets (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Current Assets data on file, last reported at $267.3 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 13.54% year-over-year to $267.3 million; the trailing twelve-month figure through Mar 2026 stood at $267.3 million (down 13.54% YoY), and the FY2025 full-year result was $260.9 million, down 31.26% from the prior year.
• Current Assets rose to $267.3 million in Q1 2026, from $260.9 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $666.8 million in Q2 2022 to a low of $260.9 million in Q4 2025.
• A 5-year average of $487.5 million and a median of $534.2 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets gained 4.53% in 2022 and tumbled 43.54% in 2025, its largest moves.
• Tracing LYEL's Current Assets over 5 years: stood at $651.3 million in 2022, then decreased by 14.83% to $554.7 million in 2023, then tumbled by 31.57% to $379.6 million in 2024, then tumbled by 31.26% to $260.9 million in 2025, then gained by 2.44% to $267.3 million in 2026.
• Business Quant data shows LYEL's Current Assets at $267.3 million in Q1 2026, $260.9 million in Q4 2025, and $328.2 million in Q3 2025.